ProPhase Labs stock under pressure as low-priced trading persists

Published on 09/18/2026 at 10:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

ProPhase Labs stock trades at around USD 0.01 as of September 17, 2026, reflecting a tiny market capitalization and high volatility. Recent diagnostics revenue and earnings figures frame the risk-reward profile for speculative investors.

PRPH, US74345W1080, Illustration mit AI erstellt.

ProPhase Labs, Inc. stock (ISIN US74345W1080) continues to trade at a very low price level, with the shares quoted at about USD 0.0134 on Nasdaq as of September 17, 2026, implying a market capitalization near USD 208,940 and underlining the speculative nature of the diagnostics and research company.

Micro-cap valuation and trading metrics

Per recent Nasdaq-linked price data, ProPhase Labs stock was indicated at USD 0.0134 on September 17, 2026, which places the shares deep in penny-stock territory in USD terms and reflects a market capitalization of approximately USD 208,940 based on the reported outstanding share count at that time.

At such a low absolute price level, even small intraday moves can translate into double-digit percentage swings, meaning short-term volatility is an inherent feature of ProPhase Labs stock and investors need to be aware that modest changes in sentiment or liquidity can have a disproportionate impact on the percentage performance of the shares.

Recent diagnostics revenue and earnings performance

According to ProPhase Labs in its most recently available filings for the latest fiscal year within the last 24 months, the company reported diagnostics-related and consumer health revenues in the low tens of millions of USD, illustrating that the underlying business scale is far larger than the micro-cap equity valuation would suggest.

In that same recent reporting period, ProPhase Labs disclosed net income figures that fluctuated around break-even, with one quarter showing a small profit and another a modest loss, highlighting that earnings are still sensitive to shifts in test volumes, product mix and cost discipline at the company level.

Earnings trends and margin comparison

Based on the company information provided through ProPhase Labs, revenue in the most recent fiscal year was higher than in the immediately preceding fiscal year, indicating a positive year-over-year comparison in top-line development even though the absolute figures remain modest by large-cap standards.

At the same time, gross margin remained solidly in positive territory in that fresh reporting window, but operating margin and net margin were compressed due to ongoing investment in sales, marketing and research, which means that incremental revenue growth will have to be carefully managed to translate into sustainable profitability for ProPhase Labs over the medium term.

Speculative investor perspective on ProPhase Labs stock

For investors, the combination of a roughly USD 0.0134 share price as of September 17, 2026 in Nasdaq trading, a market capitalization below USD 0.25 million and revenue in the low tens of millions of USD from recent filings with ProPhase Labs paints a picture of a company whose equity valuation is extremely leveraged to changes in market perception.

The quantified comparison between the revenue scale and the small market capitalization shows that the valuation multiple applied by the market is far below what is typical for profitable diagnostics and research peers, which can be interpreted either as a signal of significant perceived risk or, conversely, as a potential opportunity for investors who believe the company can stabilize earnings and improve margins.

Price level as of mid-September 2026

As of the close on September 17, 2026, the reference price for ProPhase Labs stock on Nasdaq stands at approximately USD 0.0134, a level that underscores the micro-cap character of the shares and the high sensitivity of percentage returns to any future changes in trading interest or corporate news.